The Cross-Border Data Innovation Lab of International Business Cooperation Zone has been authorized by the Pudong New Area Data Bureau.
This marks a key step for Waigaoqiao in advancing the market-based allocation of data factors, facilitating compliant cross-border data flows, and supporting the high-quality development of the biopharmaceutical industry.
The Cross-Border Data Innovation Lab is led by the Waigaoqiao Group and operated by its subsidiary biopharmaceutical company. Leveraging the dual-zone linkage and institutional openness advantages of the bonded area and the Oriental Hub International Business Cooperation Zone, the lab focuses on key fields like biopharmaceuticals. It aims to explore compliant development pathways for public and industrial data, with a primary focus on application areas such as real-world research, analysis of medical service pricing and payment policies, rare disease research, and cross-border R&D collaboration.
Addressing needs in innovative drug R&D, medical device market access, and cutting-edge technology evaluation, Waigaoqiao will accelerate the establishment of a full-chain advancement model encompassing scenario validation, data connection, compliant application, and effectiveness evaluation. This aims to provide a practical example of how data elements can better serve the real economy.
As the pioneering site of China's first bonded zone and free trade zone, Waigaoqiao has attracted a number of biopharmaceutical enterprises with mature cross-border operational capabilities through its exploration and accumulation of institution-oriented openness, forming a foundation for a competitive industrial cluster.
Building upon this unique industrial ecosystem, the lab will further strengthen collaboration with regulatory bodies, medical institutions, and industry players. It will prudently advance pilot scenarios related to cross-border data, exploring replicable and scalable data application pathways.
